$INSP
Inspire Medical Systems, Inc.

2020 Q4 Form 10-Q Financial Statement

#000160955020000048 Filed on November 02, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $46.01M $35.84M $20.86M
YoY Change 71.0% 71.81% 59.81%
Cost Of Revenue $7.160M $5.211M $3.456M
YoY Change 68.87% 50.78% 40.09%
Gross Profit $38.85M $30.63M $17.41M
YoY Change 71.39% 75.98% 64.41%
Gross Profit Margin 84.44% 85.46% 83.43%
Selling, General & Admin $38.63M $33.22M $22.43M
YoY Change 37.03% 48.11% -9.47%
% of Gross Profit 99.44% 108.45% 128.86%
Research & Development $7.290M $7.307M $3.623M
YoY Change 93.37% 101.68% 104.57%
% of Gross Profit 18.77% 23.85% 20.81%
Depreciation & Amortization $250.0K $210.0K $130.0K
YoY Change 56.25% 61.54% 30.0%
% of Gross Profit 0.64% 0.69% 0.75%
Operating Expenses $45.91M $40.52M $26.06M
YoY Change 43.65% 55.52% 71.02%
Operating Profit -$7.062M -$9.892M -$8.651M
YoY Change -24.01% 14.35% 86.08%
Interest Expense -$460.0K $533.0K $529.0K
YoY Change -284.0% 0.76% -22.21%
% of Operating Profit
Other Income/Expense, Net $60.00K -$406.0K $404.0K
YoY Change 500.0% -200.5% -1018.18%
Pretax Income -$7.460M -$10.30M -$8.247M
YoY Change -17.48% 24.87% 75.73%
Income Tax $30.00K $100.0K $0.00
% Of Pretax Income
Net Earnings -$7.484M -$10.39M -$8.247M
YoY Change -17.58% 25.92% 75.73%
Net Earnings / Revenue -16.27% -28.97% -39.53%
Basic Earnings Per Share -$0.39
Diluted Earnings Per Share -$277.1K -$0.39 -$344.6K
COMMON SHARES
Basic Shares Outstanding 26.94M shares 26.84M shares 23.91M shares
Diluted Shares Outstanding 26.84M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $234.4M $234.6M $151.6M
YoY Change 56.79% 54.75% 25.91%
Cash & Equivalents $190.5M $178.7M $48.04M
Short-Term Investments $43.80M $55.90M $103.6M
Other Short-Term Assets $2.000M $2.200M $3.200M
YoY Change -9.09% -31.25% 220.0%
Inventory $8.479M $8.966M $4.675M
Prepaid Expenses $1.965M $2.219M $3.200M
Receivables $25.06M $21.10M $10.99M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $269.9M $266.9M $170.5M
YoY Change 58.15% 56.59% 31.17%
LONG-TERM ASSETS
Property, Plant & Equipment $5.311M $4.309M $2.757M
YoY Change 74.42% 56.29% 260.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $9.600M
YoY Change -100.0% -100.0%
Other Assets $204.0K $400.0K $400.0K
YoY Change -46.46% 0.0%
Total Long-Term Assets $11.32M $4.861M $12.76M
YoY Change 6.62% -61.91% 1568.37%
TOTAL ASSETS
Total Short-Term Assets $269.9M $266.9M $170.5M
Total Long-Term Assets $11.32M $4.861M $12.76M
Total Assets $281.2M $271.8M $183.2M
YoY Change 55.14% 48.33% 40.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.200M $6.700M $4.800M
YoY Change 60.0% 39.58% 100.0%
Accrued Expenses $13.52M $11.46M $7.865M
YoY Change 9.03% 45.65% 58.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.73M $18.20M $12.70M
YoY Change 22.95% 43.26% 67.25%
LONG-TERM LIABILITIES
Long-Term Debt $24.70M $24.70M $24.50M
YoY Change 0.82% 0.82% -1.21%
Other Long-Term Liabilities $85.00K $74.00K
YoY Change 112.5%
Total Long-Term Liabilities $30.72M $74.00K $24.50M
YoY Change 25.06% -99.7% -1.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.73M $18.20M $12.70M
Total Long-Term Liabilities $30.72M $74.00K $24.50M
Total Liabilities $51.44M $42.96M $37.17M
YoY Change 24.2% 15.58% 14.69%
SHAREHOLDERS EQUITY
Retained Earnings -$237.3M -$229.9M -$171.1M
YoY Change 31.75% 34.36% 20.36%
Common Stock $27.00K $27.00K $24.00K
YoY Change 12.5% 12.5% 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $229.7M $228.8M $146.1M
YoY Change
Total Liabilities & Shareholders Equity $281.2M $271.8M $183.2M
YoY Change 55.14% 48.33% 40.17%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$7.484M -$10.39M -$8.247M
YoY Change -17.58% 25.92% 75.73%
Depreciation, Depletion And Amortization $250.0K $210.0K $130.0K
YoY Change 56.25% 61.54% 30.0%
Cash From Operating Activities -$4.110M -$8.910M -$2.940M
YoY Change -32.4% 203.06% -17.42%
INVESTING ACTIVITIES
Capital Expenditures -$610.0K -$1.210M -$1.070M
YoY Change 38.64% 13.08%
Acquisitions
YoY Change
Other Investing Activities $12.00M -$24.72M $560.0K
YoY Change -161.38% -4514.29% -100.61%
Cash From Investing Activities $11.40M -$25.93M -$500.0K
YoY Change -157.03% 5086.0% -99.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.530M 2.310M 190.0K
YoY Change 408.99% 1115.79% 375.0%
NET CHANGE
Cash From Operating Activities -4.110M -8.910M -2.940M
Cash From Investing Activities 11.40M -25.93M -500.0K
Cash From Financing Activities 4.530M 2.310M 190.0K
Net Change In Cash 11.82M -32.53M -3.250M
YoY Change -146.94% 900.92% -96.6%
FREE CASH FLOW
Cash From Operating Activities -$4.110M -$8.910M -$2.940M
Capital Expenditures -$610.0K -$1.210M -$1.070M
Free Cash Flow -$3.500M -$7.700M -$1.870M
YoY Change -37.94% 311.76% -47.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
001-38468
dei Entity Central Index Key
EntityCentralIndexKey
0001609550
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201613Member
CY2020Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OperatingLeaseRightOfUseAsset
CY2020Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Inspire Medical Systems, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1377674
dei Entity Address Address Line1
EntityAddressAddressLine1
5500 Wayzata Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1600
dei Entity Address City Or Town
EntityAddressCityOrTown
Golden Valley
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55416
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
672-4357
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
INSP
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26935172 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178705000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22860000 USD
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
55932000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
126605000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
42000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
48000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21101000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13131000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
8966000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5834000 USD
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2219000 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2206000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
266923000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
170636000 USD
CY2020Q3 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
6276000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4309000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3045000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
171000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
915000 USD
CY2020Q3 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
381000 USD
CY2019Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
381000 USD
CY2020Q3 us-gaap Assets
Assets
271784000 USD
CY2019Q4 us-gaap Assets
Assets
181253000 USD
CY2020Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6743000 USD
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4459000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11455000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12397000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18198000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16856000 USD
CY2020Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
24689000 USD
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24522000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
40000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
42961000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
41418000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26920845 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26920845 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24107350 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24107350 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
24000 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
458586000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
319865000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
73000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9404000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
102000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-229863000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180156000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
228823000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
139835000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
271784000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181253000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35842000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20862000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69372000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55144000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5211000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3456000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10462000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
30631000 USD
CY2019Q3 us-gaap Gross Profit
GrossProfit
17406000 USD
us-gaap Gross Profit
GrossProfit
58910000 USD
us-gaap Gross Profit
GrossProfit
45740000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7307000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3623000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18807000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9072000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33216000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22434000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
89249000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
62272000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
40523000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
26057000 USD
us-gaap Operating Expenses
OperatingExpenses
108056000 USD
us-gaap Operating Expenses
OperatingExpenses
71344000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9892000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8651000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-49146000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-25604000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
125000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
903000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
1015000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
3025000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
533000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
529000 USD
us-gaap Interest Expense
InterestExpense
1584000 USD
us-gaap Interest Expense
InterestExpense
1589000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
83000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-406000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
404000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-486000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1441000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10298000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8247000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49632000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24163000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-10385000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-8247000 USD
us-gaap Profit Loss
ProfitLoss
-49719000 USD
us-gaap Profit Loss
ProfitLoss
-24163000 USD
CY2020Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-81000 USD
CY2019Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
39000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-29000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
142000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10466000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8208000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49748000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24021000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26835603 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23940430 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25767497 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23713705 shares
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
139835000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
787000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2749000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
193000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-16245000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
127403000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
732000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
73000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1059000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2903000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-141000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23089000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
233594000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2312000 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3311000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-81000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10385000 USD
CY2020Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
228823000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
163999000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
166000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1391000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
68000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-8266000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
157416000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
604000 USD
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
637000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1389000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
35000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7650000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
152489000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
191000 USD
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1524000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
39000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-8247000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
146054000 USD
us-gaap Profit Loss
ProfitLoss
-49719000 USD
us-gaap Profit Loss
ProfitLoss
-24163000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
587000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
342000 USD
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
66000 USD
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
846000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
166000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
214000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
743000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
665000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8963000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4304000 USD
insp Sharebased Compensation Noncash Services
SharebasedCompensationNoncashServices
217000 USD
insp Sharebased Compensation Noncash Services
SharebasedCompensationNoncashServices
174000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
89000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
143000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
7921000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
4378000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3132000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2008000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1908000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2262000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1444000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-931000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-467000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48935000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26770000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1851000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2297000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
52721000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
143524000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
129803000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
122254000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
75231000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23567000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
531000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3831000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
961000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
124654000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
insp Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan
1059000 USD
insp Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan
637000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129544000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1067000 USD
CY2020Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
155845000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49244000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22860000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97288000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178705000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48044000 USD
us-gaap Interest Paid Net
InterestPaidNet
1422000 USD
us-gaap Interest Paid Net
InterestPaidNet
1562000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. We use significant judgment when making estimates related to the allowance for credit losses, inventory reserves, warranty reserves, and the valuation of stock-based awards. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
100000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
100000 USD
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
100000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 USD
CY2020Q3 insp Investments Allowance For Credit Loss
InvestmentsAllowanceForCreditLoss
0 USD
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0 USD
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of September 30, 2020 and December 31, 2019, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div>
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
960000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
781000 USD
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8006000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5053000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
8966000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5834000 USD
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000 USD
CY2020Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000 USD
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5901000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4050000 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1592000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1005000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4309000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3045000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000 USD
CY2020Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
10087000 USD
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
10304000 USD
CY2020Q3 us-gaap Interest Payable Current
InterestPayableCurrent
155000 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
160000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
85000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
828000 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1128000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1105000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11455000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12397000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 insp Operating Lease Remaining Lease Discount Rate Percent
OperatingLeaseRemainingLeaseDiscountRatePercent
0.080
CY2020Q3 us-gaap Advertising Expense
AdvertisingExpense
6800000 USD
CY2019Q3 us-gaap Advertising Expense
AdvertisingExpense
4700000 USD
us-gaap Advertising Expense
AdvertisingExpense
18200000 USD
us-gaap Advertising Expense
AdvertisingExpense
12600000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1800000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1800000 USD
CY2020Q3 insp Operating Leases Future Minimum Payments Net Present Value
OperatingLeasesFutureMinimumPaymentsNetPresentValue
7400000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
171000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
915000 USD
CY2020Q3 insp Operating Lease Liability Gross
OperatingLeaseLiabilityGross
85000 USD
CY2019Q4 insp Operating Lease Liability Gross
OperatingLeaseLiabilityGross
828000 USD
insp Operating Lease Remaining Lease Term
OperatingLeaseRemainingLeaseTerm
P0Y2M12D
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
300000 USD
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
300000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
800000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
800000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
9188000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
12250000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
3062000 USD
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
24500000 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2844164 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.41
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
124585000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
214690 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
85.03
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
493965 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
35400000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50088 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
40.11
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2514801 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
39.33
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
225640000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1098248 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
insp Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable
123823000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3311000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1524000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8963000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4304000 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
32900000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35842000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20862000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69372000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55144000 USD

Files In Submission

Name View Source Status
0001609550-20-000048-index-headers.html Edgar Link pending
0001609550-20-000048-index.html Edgar Link pending
0001609550-20-000048.txt Edgar Link pending
0001609550-20-000048-xbrl.zip Edgar Link pending
a2020-q3ex31x1.htm Edgar Link pending
a2020-q3ex31x2.htm Edgar Link pending
a2020-q3ex32x1.htm Edgar Link pending
a2020-q3ex32x2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
insp-20200930.htm Edgar Link pending
insp-20200930.xsd Edgar Link pending
insp-20200930_cal.xml Edgar Link unprocessable
insp-20200930_def.xml Edgar Link unprocessable
insp-20200930_g1.jpg Edgar Link pending
insp-20200930_htm.xml Edgar Link completed
insp-20200930_lab.xml Edgar Link unprocessable
insp-20200930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending